Search Results

You are looking at 1 - 10 of 75 items for :

  • "antiemetics" x
  • Refine by Access: All x
Clear All
Full access

Obstacles to the Implementation of Antiemetic Guidelines

Steven M. Grunberg

Compr Canc Netw 2007 ; 5 : 12 – 33 . 6 Kris MG Hesketh PJ Somerfield MR . American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006 . J Clin Oncol 2006 ; 24 : 2932 – 2947 . 7 Antiemetic

Full access

Antiemetic Studies on the NK1 Receptor Antagonist Aprepitant

John P. Stoutenburg and Harry Raftopoulos

comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting . Eur J Cancer 1997 ; 33 : 66 – 74 . 2 Grunberg SM Hansen M Deuson R : Incidence and impact of nausea/vomiting with

Full access

What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy

Eric J. Roeland, Kathryn J. Ruddy, Thomas W. LeBlanc, Ryan D. Nipp, Gary Binder, Silvia Sebastiani, Ravi Potluri, Luke Schmerold, Eros Papademetriou, Lee Schwartzberg, and Rudolph M. Navari

controlled CINV can lead to chemotherapy treatment delays, dose reductions, and increased healthcare utilization. 1 Use of prophylactic combination antiemetic regimens targeting multiple biologic mechanisms associated with CINV represent the standard of care

Full access

Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy

Ciara C. O'Sullivan, Holly K. Van Houten, Lindsey R. Sangaralingham, Alexis D. Leal, Shivani Shinde, Hongfang Liu, David Ettinger, Charles L. Loprinzi, and Kathryn J. Ruddy

% risk of emesis if no antiemetics are provided. 1 Delayed nausea and vomiting is a particular problem with HEC because it is often underestimated by nurses and physicians. 2 Effective prevention is important for maintaining quality of life. 3 , 4

Full access

Antiemetic Guidelines: Not Just for the HEC of It

Kelsey A. Klute

by both patients and physicians who voted the FDA’s approval of ondansetron in 1991 and other antiemetics in subsequent years as one of the ”Top 5 Advances in 50 Years of Modern Oncology” in ASCO’s 50th anniversary poll in 2014. 2 The second half of

Full access

BPI20-016: Comparative Study Between the Clinical Effect of Palonosetron and Granisetron as Antiemetic Therapy for Patients Receiving Highly Emetogenic Chemotherapy Regimens

Mohamed Ahmed Mahrous, Gamal Abd El Khalek El- Azab, and Hisham Ahmed Tawfik

highly emetogenic chemotherapy (HEC) such as AC protocol in breast cancer patients or cisplatin based regimens in other types of cancer. Objectives: The aim of this study was to evaluate the antiemetic efficacy of palonosetron (palono) over granisetron

Full access

Use of Acupuncture in the Control of Chemotherapy-Induced Nausea and Vomiting

Ting Bao

cancer nausea and vomiting . J Clin Oncol 2008 ; 26 : 3903 – 3910 . 2 Hickok JT Roscoe JA Morrow GR . Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of

Full access

Cannabinoids for Symptom Management and Cancer Therapy: The Evidence

Mellar P. Davis

antiemetic, analgesic, anxiolytic, anti-inflammatory, and antipsychotic effects. 6 Cannabidiol inhibits cyclooxygenase and lipoxygenases and reduces N -methyl-D-aspartate toxicity. It also activates TRPV1. 7 Palmitoylethanolamine (PEA) was first described

Full access

BPI19-019: Avoidable Acute Care Use Associated With Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin

Eric J Roeland, Thomas W. LeBlanc, Kathryn J. Ruddy, Ryan Nipp, Rebecca Clark-Snow, Rita Wickham, Gary Binder, William L. Bailey, Ravi Potluri, Luke M. Schmerold, Eros Papademetriou, and Rudolph M. Navari

department (ED) events (IP/ED) as “potentially avoidable” if involving any of 10 toxicities, including nausea or vomiting (NV). Evidence demonstrates meaningful gaps in oncologists’ adherence to antiemetic prophylaxis guidelines for highly emetogenic

Full access

BPI20-011: Prescriber-Assigned Febrile Neutropenia and Emetic Risks Compared to the NCCN Risk Classification for Cancer Treatment Regimens

Kimberly Rose Hedstrom, Margaret Rausa, Eric Gratias, and Stephen Hamilton

NCCN were assigned as potentially wasteful MGF and antiemetic use, as these drugs are not recommended for primary prophylaxis in the low risk setting. Savings were estimated using average sales price (ASP) + 6% administered in a non-facility setting